Covid-19: Lancet study finds no significant clinical benefits of antiviral drug remdesivir

Participants were randomly assigned to either daily infusions of remdesivir -- 158 patients were given 200mg on day 1 followed by 100mg on days 210 -- or placebo infusions, given to 79 patients for 10 days.
Market Update
SENSEX 31,622.48 -187.07(%)
NIFTY 9,898.00 -54.2(%)